Transitional CXCL14+ cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma
Abstract Background The heterogeneity of cancer‐associated fibroblasts (CAFs) has become a crucial focus in understanding cancer biology and treatment response, revealing distinct subpopulations with specific roles in tumor pathobiology. CAFs have also been shown to promote resistance in lung cancer...
Saved in:
| Main Authors: | Weijiao Xu, Haitang Yang, Ke Xu, Anshun Zhu, Sean R. R. Hall, Yunxuan Jia, Baicheng Zhao, Enshuo Zhang, Gang Liu, Jianlin Xu, Thomas M. Marti, Ren‐Wang Peng, Patrick Dorn, Yongliang Niu, Xufeng Pan, Yajuan Zhang, Feng Yao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Clinical and Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ctm2.70281 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Application of EGFR-TKIs in brain tumors, a breakthrough in future?
by: Shiying Feng, et al.
Published: (2025-04-01) -
Editorial: EGFR-TKIs for lung cancer treatment: development, application, and side effects
by: Qinglin Shen, et al.
Published: (2025-05-01) -
Proteomic Profiling Reveals TPR and FGA as Predictive Serum Biomarkers of Relapse to First- and Second-Generation EGFR-TKIs in Advanced Lung Adenocarcinoma
by: Pritsana Raungrut, et al.
Published: (2025-06-01) -
GLUT1 sensitizes tumor cells to EGFR-TKIs by binding with activated EGFR and regulating its downstream signaling pathways
by: Zhangrong Xie, et al.
Published: (2025-05-01) -
Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
by: Linwu Kuang, et al.
Published: (2025-03-01)